Brokerages Set Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Target Price at $28.00

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) have been assigned an average rating of “Reduce” from the nine research firms that are covering the stock, MarketBeat reports. Four research analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $28.00.

A number of equities analysts have issued reports on the company. Wall Street Zen lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Erste Group Bank downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Truist Financial set a $28.00 price target on shares of Fresenius Medical Care AG & Co. KGaA in a report on Monday, January 5th. The Goldman Sachs Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 20th. Finally, Jefferies Financial Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a report on Tuesday, February 24th.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.2%

NYSE FMS opened at $22.45 on Thursday. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $20.94 and a 52 week high of $30.46. The stock has a market capitalization of $12.54 billion, a PE ratio of 11.75, a price-to-earnings-growth ratio of 2.12 and a beta of 0.89. The company has a quick ratio of 0.92, a current ratio of 1.26 and a debt-to-equity ratio of 0.40. The firm has a 50 day moving average of $23.09 and a two-hundred day moving average of $24.02.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings data on Saturday, February 14th. The company reported $1.69 earnings per share for the quarter. The company had revenue of $5.95 billion during the quarter. Fresenius Medical Care AG & Co. KGaA had a net margin of 5.03% and a return on equity of 8.73%. As a group, research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Several large investors have recently modified their holdings of the stock. Factory Mutual Insurance Co. acquired a new stake in Fresenius Medical Care AG & Co. KGaA during the third quarter valued at approximately $1,769,000. Pzena Investment Management LLC lifted its holdings in Fresenius Medical Care AG & Co. KGaA by 1.0% during the 3rd quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock worth $390,128,000 after buying an additional 153,870 shares during the last quarter. Teachers Retirement System of The State of Kentucky grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 8.3% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 816,200 shares of the company’s stock worth $21,491,000 after acquiring an additional 62,700 shares in the last quarter. Todd Asset Management LLC grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 5.2% in the 3rd quarter. Todd Asset Management LLC now owns 1,303,424 shares of the company’s stock worth $34,319,000 after acquiring an additional 64,311 shares in the last quarter. Finally, Searle & CO. increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 246.6% in the 3rd quarter. Searle & CO. now owns 80,725 shares of the company’s stock valued at $2,125,000 after acquiring an additional 57,437 shares during the last quarter. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.